AIMS: To assess the single-dose pharmacokinetics and tolerability of pegylated interferon-alpha2b (PEG-Intron) in young and elderly healthy subjects. METHODS: In this parallel-design study, a single 1 microg x kg(-1) PEG-Intron dose was given subcutaneously to 24 subjects in the age groups 20-45, 65-69, 70-74 and 75-80 years (n = 6/group). Blood sampling and tolerability assessments were performed up to 168 h postdose. RESULTS: The pharmacokinetic parameters were similar in all age groups. The elderly to young subject ratios for Cmax were 91.1, 79.5, and 107% for the 65-69 years, 70-74 years and 75-80 years groups, respectively. The corresponding values for AUC(0- infinity ) and CL/F were 111, 102 and 108%, and 82.5, 95.8 and 86.4%, respectively. Mean differences from the 20 to 45 years group and the 65-69 years, 70-74 years and 75-80 years groups for PEG-Intron Vd/F were 108, 128 and 104%, respectively. None of these differences was statistically significant based on ANOVA. Results from a Dunnett's test (as post hoc assessment) confirmed that the pharmacokinetic parameters of Group II, Group III or Group IV were not different from those of Group I. Almost all (23/24; 96%) subjects reported typical interferon-alpha side-effects (flu-like symptoms, headache). One elderly patient had a myocardial infarction 12 h postdose, but recovered fully. CONCLUSIONS: There are no pharmacokinetic reasons for initial dose adjustment of PEG-Intron based on age.
RCT Entities:
AIMS: To assess the single-dose pharmacokinetics and tolerability of pegylated interferon-alpha2b (PEG-Intron) in young and elderly healthy subjects. METHODS: In this parallel-design study, a single 1 microg x kg(-1) PEG-Intron dose was given subcutaneously to 24 subjects in the age groups 20-45, 65-69, 70-74 and 75-80 years (n = 6/group). Blood sampling and tolerability assessments were performed up to 168 h postdose. RESULTS: The pharmacokinetic parameters were similar in all age groups. The elderly to young subject ratios for Cmax were 91.1, 79.5, and 107% for the 65-69 years, 70-74 years and 75-80 years groups, respectively. The corresponding values for AUC(0- infinity ) and CL/F were 111, 102 and 108%, and 82.5, 95.8 and 86.4%, respectively. Mean differences from the 20 to 45 years group and the 65-69 years, 70-74 years and 75-80 years groups for PEG-Intron Vd/F were 108, 128 and 104%, respectively. None of these differences was statistically significant based on ANOVA. Results from a Dunnett's test (as post hoc assessment) confirmed that the pharmacokinetic parameters of Group II, Group III or Group IV were not different from those of Group I. Almost all (23/24; 96%) subjects reported typical interferon-alpha side-effects (flu-like symptoms, headache). One elderly patient had a myocardial infarction 12 h postdose, but recovered fully. CONCLUSIONS: There are no pharmacokinetic reasons for initial dose adjustment of PEG-Intron based on age.
Authors: P Glue; J W Fang; R Rouzier-Panis; C Raffanel; R Sabo; S K Gupta; M Salfi; S Jacobs Journal: Clin Pharmacol Ther Date: 2000-11 Impact factor: 6.875
Authors: E Chatelut; L Rostaing; N Grégoire; J L Payen; A Pujol; J Izopet; G Houin; P Canal Journal: Br J Clin Pharmacol Date: 1999-04 Impact factor: 4.335
Authors: P Glue; R Rouzier-Panis; C Raffanel; R Sabo; S K Gupta; M Salfi; S Jacobs; R P Clement Journal: Hepatology Date: 2000-09 Impact factor: 17.425
Authors: Ronald M Bukowski; Craig Tendler; David Cutler; Esther Rose; Mark M Laughlin; Paul Statkevich Journal: Cancer Date: 2002-07-15 Impact factor: 6.860
Authors: Samir K Gupta; Suzanne K Swan; Thomas Marbury; William Smith; Sherwyn Schwartz; Karen Kolz; David L Cutler Journal: Br J Clin Pharmacol Date: 2007-06-06 Impact factor: 4.335
Authors: Manuela G Neuman; Kevin Sha; Rustan Esguerra; Sam Zakhari; Robert E Winkler; Nir Hilzenrat; Jonathan Wyse; Curtis L Cooper; Devanshi Seth; Mark D Gorrell; Paul S Haber; Geoffrey W McCaughan; Maria A Leo; Charles S Lieber; Mihai Voiculescu; Eugenia Buzatu; Camelia Ionescu; Jozsef Dudas; Bernhard Saile; Giuliano Ramadori Journal: Dig Dis Sci Date: 2008-06 Impact factor: 3.487